The Quantellect read.As of Nov 19, 2026, 6 active firms cover Integra LifeSciences Holdings: 0 rate it Buy or better, 6 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets are tightly clustered, $15.00 to $19.00, so the covering firms are broadly aligned. The average target of $16.40 sits 18% above the current $13.86. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.49 next quarter toward $2.37 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Neutral
Strong Buy00%
Buy00%
Neutral6100%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$16.40
+18.3% upside
Average target across 5 active firms as of Nov 19, 2026 vs $13.86 current
Highest Target$19.00
Average Target$16.40
Lowest Target$15.00
Detailed analyst forecasts for IART
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 0 of 6 active firms rate IART a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IART EPS & revenue forecast
EPS · NEXT QUARTER
$0.49
Range $0.41 – $0.60 · 8 analysts · -9% YoY
Next period, 8 analysts expect Integra LifeSciences Holdings to earn $0.49 a share (range $0.41 – $0.60), versus $0.54 a year earlier. Full-year consensus is $2.34, growing to $2.37 the year after.
REVENUE · NEXT QUARTER
$388.2M
Range $383.7M – $395.1M · 8 analysts · -1% YoY
Revenue is expected to reach $388.2M (range $383.7M – $395.1M), -1.0% year-over-year. Full-year consensus is $1.6B, rising to $1.7B next year.
Top analysts covering Integra LifeSciences Holdings
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IART.
#1
Joanne Wuensch
Citigroup · Rank #35
Neutral
$14.00+1.0% to target
Overall win rate
51%
+ Follow
#2
JB
Jayson Bedford
Raymond James · Rank #191
Neutral
No targeton IART
Overall win rate
44%
+ Follow
#3
Ryan Zimmerman
BTIG · Rank #212
Neutral
No targeton IART
Overall win rate
37%
+ Follow
#4
David Turkaly
JMP Securities · Rank #453
Buy
$25.00+80.4% to target
Overall win rate
35%
+ Follow
#5
Richard Newitter
Truist Securities · Rank #532
Neutral
$15.00+8.2% to target
Overall win rate
30%
+ Follow
IART stock forecast FAQ
What is IART's average 12-month price target?+
The 5 active firms with a live target average $16.40 for Integra LifeSciences Holdings over the next 12 months, ranging from a $19.00 high to a $15.00 low, as of Nov 19, 2026.
Is IART stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 6 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 6 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IART?+
The Street-high target is $19.00 (UBS), and the Street-low is $15.00 (Truist Securities). The average of all 5 active-firm targets is $16.40.
How many active Wall Street firms cover IART?+
6 active firms have a recognized rating on Integra LifeSciences Holdings as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IART?+
Among analysts who currently cover IART, Joanne Wuensch of Citigroup has the strongest overall Quantellect track record (Rank #35). Their current call is Neutral with a $14.00 target.
What is Integra LifeSciences Holdings's projected EPS for next quarter?+
The consensus estimate is $0.49 per share (range $0.41 – $0.60) across 8 analysts. Full-year EPS is projected at $2.34, rising to $2.37 the following year.
How much revenue is Integra LifeSciences Holdings expected to report next quarter?+
Consensus revenue is $388.2M (range $383.7M – $395.1M). Full-year revenue is projected at $1.6B, growing to $1.7B next year.
Have analysts been upgrading or downgrading IART lately?+
As of Nov 19, 2026, 0 of 6 active firms rate IART a Buy (6 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IART calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.